Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 3 study titled ‘MagnetisMM-32’ to evaluate the efficacy of elranatamab, a new treatment for relapsed/refractory multiple myeloma (MM), against standard combination therapies. This study is significant as it targets patients who have previously undergone anti-CD38 antibody and lenalidomide treatments, aiming to provide an alternative for those with recurring or resistant MM.
The study tests elranatamab, an experimental drug administered subcutaneously, against three established combination therapies involving drugs like elotuzumab, pomalidomide, bortezomib, and carfilzomib. The goal is to assess the safety and effectiveness of elranatamab as a monotherapy compared to these combinations.
This interventional study uses a randomized, parallel assignment model with no masking, focusing primarily on treatment outcomes. Participants are divided into two groups: one receiving elranatamab and the other receiving a combination therapy chosen by the study doctor.
The study officially started on February 8, 2024, with an estimated completion date in 2025. The last update was submitted on August 4, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly impact Pfizer’s stock performance by potentially introducing a new treatment option in the competitive MM market. Success in this trial may enhance investor confidence and position Pfizer as a leader in innovative cancer therapies, especially against competitors in the oncology sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.